Abstract
The tumor suppressor protein p53 plays an important role in maintaining genomic integrity. p53 possesses an intrinsic 3→ 5 exonuclease activity. The presence of exonuclease activity has been implicated in the prevention of mutator phenotype and in acquired resistance to chemotherapeutic agents. p53 may act as proofreading exonuclease for DNA polymerases during DNA replication. The recombinant wild-type p53 can proofread for various exonuclease-deficient cellular and viral DNA polymerases. The preferential excision of mismatched nucleotides from DNA by 3→5 exonuclease activity enhances the fidelity of DNA synthesis, thus providing a biochemical mechanism to reduce mutations caused by incorporation of mismatched nucleotides. P53 exonuclease activity for different mismatches is dependent upon the nature of the mispair. The observed specificity of mismatch excision indicates that p53 exonucleolytic proofreading preferentially repairs transversion mutations. Interestingly, p53 exonuclease activity preferentially removes the same base that is less efficiently incorporated and extended by the DNA polymerase. Hence, the proofreading activity of p53 may limit the transversion mutations, indicating that the mutation spectra might be affected by the actions of DNA polymerase and p53-exonuclease. p53 was found in the nucleus and in the cytoplasm of the cell. In cytoplasmic extracts, non-induced p53, displays high level of 3→ 5 exonuclease activity in comparison to nuclear extracts. P53 may recognize and remove incorporated nucleoside analogs from DNA in vitro, in whole cells and in cytoplasm. These findings raise the possibility that resistance to anti-cancer and anti-viral nucleoside analogs, in part, may involve the excision of incorporated drug during DNA synthesis.
Keywords: p53, 3'→ 5'exonuclease activity, genomic stability, nucleoside analogs
Current Cancer Therapy Reviews
Title: A Role for Tumor Suppressor Protein p53 in the Fidelity of DNA Synthesis and Resistance Towards Nucleoside Analogs
Volume: 2 Issue: 3
Author(s): Mary Bakhanashvili and Galia Rahav
Affiliation:
Keywords: p53, 3'→ 5'exonuclease activity, genomic stability, nucleoside analogs
Abstract: The tumor suppressor protein p53 plays an important role in maintaining genomic integrity. p53 possesses an intrinsic 3→ 5 exonuclease activity. The presence of exonuclease activity has been implicated in the prevention of mutator phenotype and in acquired resistance to chemotherapeutic agents. p53 may act as proofreading exonuclease for DNA polymerases during DNA replication. The recombinant wild-type p53 can proofread for various exonuclease-deficient cellular and viral DNA polymerases. The preferential excision of mismatched nucleotides from DNA by 3→5 exonuclease activity enhances the fidelity of DNA synthesis, thus providing a biochemical mechanism to reduce mutations caused by incorporation of mismatched nucleotides. P53 exonuclease activity for different mismatches is dependent upon the nature of the mispair. The observed specificity of mismatch excision indicates that p53 exonucleolytic proofreading preferentially repairs transversion mutations. Interestingly, p53 exonuclease activity preferentially removes the same base that is less efficiently incorporated and extended by the DNA polymerase. Hence, the proofreading activity of p53 may limit the transversion mutations, indicating that the mutation spectra might be affected by the actions of DNA polymerase and p53-exonuclease. p53 was found in the nucleus and in the cytoplasm of the cell. In cytoplasmic extracts, non-induced p53, displays high level of 3→ 5 exonuclease activity in comparison to nuclear extracts. P53 may recognize and remove incorporated nucleoside analogs from DNA in vitro, in whole cells and in cytoplasm. These findings raise the possibility that resistance to anti-cancer and anti-viral nucleoside analogs, in part, may involve the excision of incorporated drug during DNA synthesis.
Export Options
About this article
Cite this article as:
Bakhanashvili Mary and Rahav Galia, A Role for Tumor Suppressor Protein p53 in the Fidelity of DNA Synthesis and Resistance Towards Nucleoside Analogs, Current Cancer Therapy Reviews 2006; 2 (3) . https://dx.doi.org/10.2174/157339406777934672
DOI https://dx.doi.org/10.2174/157339406777934672 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Asbestos-Related Diseases: Still a Concern in Emerging Economies in the Absence of an International Ban
Current Respiratory Medicine Reviews Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Current Signal Transduction Therapy Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry From ImmunoToxins to ImmunoRNases
Current Pharmaceutical Biotechnology IgA/IgM Responses to Gram-Negative Bacteria are not Associated with Perinatal Depression, but with Physio-somatic Symptoms and Activation of the Tryptophan Catabolite Pathway at the End of Term and Postnatal Anxiety
CNS & Neurological Disorders - Drug Targets Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments
Current Clinical Pharmacology Pharmacological Interventions for the Prevention and Treatment of Kidney Injury Induced by Radiotherapy: Molecular Mechanisms and Clinical Perspectives
Current Molecular Pharmacology A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Corticoisteroid-Induced Apoptosis in Hematological Malignancies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Histone Deacetylase Inhibitors in Tumor Immunotherapy
Current Medicinal Chemistry Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation
Current Pharmaceutical Design Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review
Anti-Cancer Agents in Medicinal Chemistry 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry